Agomelatine Side Effects: Common, Severe Risks & More

Agomelatine (Valdoxan) carries a side effect profile that sets it apart from most antidepressants—headache, nausea, and dizziness occur most often, while liver function monitoring represents its most critical safety consideration. Clinical trials and real-world data show most adverse effects are mild to moderate and resolve within weeks.

Drug class: Atypical antidepressant · Most common side effects: Headache, nausea, dizziness · Other frequent effects: Drowsiness, fatigue, insomnia · Key monitoring need: Liver function

What are the common side effects of agomelatine?

Clinical trial data consistently shows headache, nausea, and dizziness as the three most frequently reported adverse events. A pooled analysis across multiple studies found treatment-emergent adverse events (TEAEs) occurred in 53% of agomelatine patients versus 52% of placebo patients—a difference so small it falls within statistical noise (PMC Critical appraisal). Most TEAEs were mild to moderate, with only 4.7% of patients discontinuing due to side effects compared to 4.8% on placebo.

Headache

Headache tops the list of most frequently reported adverse events across clinical trials and patient registries. The effect tends to be most pronounced during the first two weeks, often resolving without intervention as the body adjusts. Data from PMC studies shows headache rates in agomelatine patients were comparable to or slightly lower than placebo in some comparisons—a counterintuitive finding that suggests headache may not be directly drug-related in all cases (PMC Critical appraisal).

Nausea and vomiting

Nausea is common but appears less frequent than with many other antidepressants. A head-to-head comparison with paroxetine found nausea was significantly more common with the SSRI than with agomelatine or placebo (PMC Critical appraisal). Patients aged 65 and older showed TEAE rates of 63.3% on agomelatine versus 59.2% on placebo, with gastrointestinal symptoms accounting for a portion of these events (PMC Efficacy and tolerability).

Dizziness and drowsiness

Dizziness occurs more frequently with agomelatine than with placebo in clinical trials—unlike headache and nausea, which sometimes showed equivalent or lower rates than control groups. This effect appears consistent enough that it’s one of the few adverse events where agomelatine clearly differs from placebo (PMC Critical appraisal). Drowsiness and somnolence are also reported, though they tend to be transient. Patients should be cautious about driving or operating machinery until they understand how agomelatine affects them individually.

Insomnia and fatigue

Despite agomelatine’s melatonergic properties—designed to help regulate sleep-wake cycles—some patients report insomnia, abnormal dreams, and sleep disturbances. This paradox has been documented in patient forums and clinical observation: while the drug targets melatonin receptors to promote sleep initiation, it may disrupt sleep architecture in certain individuals (Patsnap Synapse). Fatigue is equally common, and patients should expect both effects to be most pronounced during the initial adjustment period.

What are the severe side effects of agomelatine?

The most serious risks associated with agomelatine revolve around liver function. Clinical trials and regulatory reviews have documented rare hepatotoxic reactions, including cases of jaundice and hepatitis. Most agomelatine adverse events were mildly to moderately severe, but these liver-related events require vigilance (PMC Efficacy and tolerability).

Liver-related risks

Australian regulators flagged particular concerns about transaminase elevations exceeding three times the upper limit of normal (3× ULN), noting these occurred more frequently at the 50mg dose and were more common in female patients (TGA AusPAR). The mechanism involves elevated liver enzymes—specifically ALT and AST—which can progress to liver injury if undetected. Signs of liver problems include dark urine, light-coloured stools, yellowing of the skin or eyes (jaundice), upper-right abdominal pain, and unusual tiredness. Patient-oriented resources emphasize the need for regular liver tests precisely because these events are rare but potentially severe (YoungMinds).

Rare serious reactions

Serious adverse events occurred in 4.1% of patients at 25mg and 4.4% at 50mg, compared to 4.1% on placebo—virtually identical rates, suggesting most serious events may not be directly attributable to agomelatine (PMC Critical appraisal). Suicide attempts were reported in 0.6% of agomelatine patients versus 0.4% on placebo—a small numerical difference that warrants monitoring in high-risk patients. Allergic reactions (difficulty breathing, swelling of face, eyelids, lips, tongue, or throat) are rare but require immediate medical attention when they occur.

What not to take with agomelatine?

Agomelatine has specific interaction concerns that stem from how it’s metabolized in the liver. Patients should disclose all medications, supplements, and herbal products to their prescriber before starting treatment.

Drug interactions

Agomelatine is metabolized primarily by CYP1A2 and CYP2C9/19 enzymes, making it susceptible to interactions with drugs that inhibit or induce these pathways. Fluvoxamine, a strong CYP1A2 inhibitor, is explicitly contraindicated due to its potential to dramatically increase agomelatine plasma concentrations. Other CYP1A2 inhibitors (such as certain quinolone antibiotics) require similar caution. Alcohol should be avoided or used sparingly, as both substances affect liver function and combining them may increase hepatic stress.

Contraindications

Agomelatine should not be used in patients with hepatic impairment (cirrhosis, active hepatitis) due to the documented risk of hepatotoxic reactions. Patients with severe renal impairment should also exercise caution, though the evidence for dose adjustment in this population is less clear. Patients should inform prescribers of any history of liver disease, alcohol dependency, or current liver enzyme abnormalities before treatment initiation.

How long can you stay on agomelatine?

Duration of treatment depends on individual response, the condition being treated, and tolerability. There’s no rigid maximum duration, but ongoing monitoring becomes more important with prolonged use.

Duration guidelines

Clinical trials have studied agomelatine over periods ranging from 6 weeks to 2 years, with data from a retrospective study suggesting the drug maintains efficacy over extended treatment periods (Wiley Online Library). In elderly patients over 65, TEAE rates were 63.3% on agomelatine versus 59.2% on placebo, with discontinuation due to adverse events at 12.8% versus 9.2%—notably higher than in younger populations (PMC Critical appraisal). Long-term studies suggest agomelatine was more tolerable than mirtazapine, resulting in less discontinuation due to intolerability, though more discontinuation due to ineffectiveness (Wiley Online Library).

Long-term use

The question of how long patients can safely stay on agomelatine remains partially answered by existing data. A two-year retrospective comparison with mirtazapine found agomelatine patients who tolerated initial treatment maintained benefits without significant new safety signals emerging (Wiley Online Library). The 50mg dose was associated with less discontinuation than might be expected from its higher liver enzyme elevation risk—a finding attributed to better efficacy at the higher dose improving adherence. Ongoing trials like the NCT05426304 study of agomelatine for poststroke depression will add to the long-term safety database (ClinicalTrials.gov).

Is agomelatine a sleeping pill?

Agomelatine is not classified or primarily designed as a sleep aid, despite its clear effects on sleep-wake regulation. Understanding how it differs from classical hypnotics helps clarify realistic expectations.

Effects on sleep

Agomelatine works through melatonin MT1 and MT2 receptor agonism combined with 5-HT2C receptor antagonism—a dual mechanism that explains both its antidepressant effects and its influence on sleep architecture. Clinical evidence shows sleep disturbances remain possible despite these melatonergic properties; insomnia, nightmares, and vivid dreams have all been documented in patient reports (Patsnap Synapse). The effect appears individual: some patients experience improved sleep initiation, while others report disrupted sleep quality. This paradox may reflect agomelatine’s complex receptor interactions—acting on both sleep-promoting melatonin pathways and arousal-related serotonin systems simultaneously.

How it makes you feel

Patient-reported experiences from YoungMinds resources describe varied responses: anxiety, nausea, stomach pain, and abnormal dreams feature prominently in user accounts (YoungMinds). The most frequent effects reported across clinical practice include headache, dizziness, somnolence, diarrhea, nausea, sedation, fatigue, and insomnia (PMC Efficacy and tolerability). Unlike traditional sedatives, agomelatine’s primary action is antidepressant with secondary sleep-normalizing effects—patients should not expect the immediate drowsiness associated with benzodiazepines or Z-drugs.

“Agomelatine appeared to be nontoxic, except for the rare adverse effect of increased liver function tests.”

— Healio Journals clinical reviewer

“There is some evidence that the incidence of this adverse event [transaminase >3× ULN] is increased at higher agomelatine doses.”

— TGA Australian regulatory assessment

“Patients who have struggled with weight gain or sexual side effects on other antidepressants may find agomelatine’s tolerability profile makes this trade-off worthwhile.”

— PMC Efficacy and tolerability review

“Agomelatine was more tolerable than mirtazapine, but could result in more discontinuation due to ineffectiveness.”

— Wiley retrospective study researchers

Agomelatine’s side effect profile sits apart from most antidepressants on the market. For patients concerned about the weight gain, sexual dysfunction, and severe gastrointestinal issues associated with SSRIs and SNRIs, it offers a meaningfully different tolerability profile—though the mandatory liver monitoring requirement represents a trade-off that suits some patients better than others. Australian regulators’ concerns about 50mg dose exposure suggest the higher dose should be reserved for patients who tolerate it well, while the near-placebo dropout rate (4.7% vs 4.8%) indicates that for those who do experience bothersome side effects, discontinuation rates are low compared to many alternatives.

Related reading: Basal Cell Cancer: Symptoms, Stages & Early Signs · How to Stop Hiccups – Proven Remedies for Adults and Babies

Frequently asked questions